PBHPrestige Consumer Healthcare In

Ticker: PBH | Filing Type: 10-Q | Filed with the SEC on: November 5, 2026 | Current Price: $44.44 | Today's Change: -16.59%

---

What Happened

Prestige Consumer Healthcare filed its quarterly report (Form 10-Q) for the second quarter of fiscal year 2027 with the SEC on November 5, 2026. The company reported revenue of $523.6 million, operating income of $151.4 million, and net income of $89.7 million for the quarter. Diluted earnings per share came in at $1.81, with basic EPS of $1.82. The market's reaction has been sharply negative, with shares falling more than 16% on the day of the filing.

---

Why It Matters

The steep single-day selloff — over 16% — signals that investors were meaningfully disappointed by the quarter's results relative to expectations, even though the company remained solidly profitable in absolute terms. For context, the structured filing data includes a historical revenue figure of $975.8 million for the full fiscal year 2019, underscoring that quarterly revenues of $523.6 million represent a substantial portion of that prior full-year baseline, but the market reaction suggests the near-term growth trajectory or margin profile did not meet current consensus. With shares now trading at $44.44, investors are reassessing the near-term earnings power of this consumer healthcare franchise. This filing coincides with StockWatch's initiation of coverage on PBH, published the same day — a full analysis is available via the linked coverage.

---

Analysis

The magnitude of today's price decline — more than 16% — is unusual for an established consumer staples-adjacent healthcare company and warrants attention beyond the headline numbers alone. While PBH remained profitable, with an operating income of $151.4 million and a net margin implied by $89.7 million in net income against $523.6 million in revenue (roughly 17%), the market's verdict suggests the results either missed expectations materially, came with cautious forward guidance, or both. Investors and analysts will want to scrutinize:

• Revenue trajectory: Whether $523.6 million in quarterly revenue represents growth, stability, or deceleration relative to prior comparable periods.
• Margin sustainability: Operating income of $151.4 million on revenue of $523.6 million implies an operating margin of approximately 28.9% — a figure that, if under pressure, could explain investor concern.
• Management commentary: Forward guidance and commentary on consumer demand trends, pricing power, and cost dynamics will be critical to understanding whether this selloff reflects a structural re-rating or a temporary market overreaction.

The sharp reaction on the same day as StockWatch's coverage initiation makes this a particularly notable moment for anyone tracking PBH. The filing is now public and the full quarterly details are available for deeper review.

---

Disclaimer

This report is a news and informational summary based solely on data extracted from Prestige Consumer Healthcare's SEC filing and publicly available market data. It does not constitute investment advice, and no buy, hold, or sell recommendation is made or implied. Investors should conduct their own due diligence and consult a qualified financial professional before making any investment decisions.

Existing Coverage

StockWatch has full coverage on PBH, published 2026-11-05. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1295947/000129594726000057/pbh-20260930.htm